{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:43:15Z","timestamp":1774359795287,"version":"3.50.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Little information is available on the relative tolerability of ceftaroline versus other cephalosporins in clinical practice. We sought to compare adverse drug reactions (ADRs) associated with ceftaroline with those associated with ceftriaxone in hospitalized patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>This was a retrospective, single-center matched cohort (according to age, indication, and duration) study of patients treated with ceftaroline or ceftriaxone at the VA St Louis Health Care System between 29 October 2010 and 28 March 2017, to compare rates of ADRs between the agents. Patients included received \u22652 doses of either medication to treat osteomyelitis, acute bacterial skin and skin structure infection, blood stream infection, pneumonia, infective endocarditis, septic arthritis, prosthetic joint infection, or empyema. The primary and secondary outcomes were the composite of any ADR during therapy and any ADR leading to premature discontinuation of therapy. The ADRs evaluated included rash, neutropenia, acute kidney injury, eosinophilia, thrombocytopenia, transaminitis, and hyperbilirubinemia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After matching, 50 patients per group were included and analyzed. An ADR occurred in 20% (10 of 50) of patients treated with ceftriaxone and 16% (8 of 50) of those treated with ceftaroline (P = .60). Two percent (1 of 50) of those treated with ceftriaxone and 16% (8 of 50) treated with ceftaroline had therapy discontinued owing to an ADR (P = .03). The most common ADR was eosinophilia (3 of 50) in the ceftriaxone group and rash (5 of 50) in the ceftaroline group. Ceftaroline therapy was identified as an independent risk factor for an ADR requiring premature discontinuation (odds ratio, 10.2; 95% confidence interval, 1.19\u201387.8; P = .03).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Although there was no difference in the rates of ADRs between patients in the ceftriaxone and ceftaroline groups, significantly more ceftaroline-treated patients required premature discontinuation.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ofid\/ofz279","type":"journal-article","created":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T06:19:55Z","timestamp":1560838795000},"source":"Crossref","is-referenced-by-count":5,"title":["Comparison of Adverse Drug Reactions Between Patients Treated With Ceftaroline or Ceftriaxone: A Single-Center, Matched Cohort Study"],"prefix":"10.1093","volume":"6","author":[{"given":"Jeffrey W","family":"Jansen","sequence":"first","affiliation":[{"name":"Pharmacy Department, SCL Health Saint Vincent Healthcare, Billings, Montana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Travis W","family":"Linneman","sequence":"additional","affiliation":[{"name":"Pharmacy Service, VA St Louis Health Care System, Missouri"},{"name":"Department of Pharmacy Practice, St Louis College of Pharmacy, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Tan","sequence":"additional","affiliation":[{"name":"College of Pharmacy, University of Illinois at Chicago"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan P","family":"Moenster","sequence":"additional","affiliation":[{"name":"Pharmacy Service, VA St Louis Health Care System, Missouri"},{"name":"Department of Pharmacy Practice, St Louis College of Pharmacy, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,6,13]]},"reference":[{"key":"2020081004074826300_CIT0001","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2146\/ajhp100181","article-title":"Ceftaroline: a new broad-spectrum cephalosporin","volume":"68","author":"Lim","year":"2011","journal-title":"Am J Health Syst Pharm"},{"key":"2020081004074826300_CIT0002","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/jcpt.12062","article-title":"Ceftaroline\u2014a cause for neutropenia","volume":"38","author":"Rimawi","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"2020081004074826300_CIT0003","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.2146\/ajhp130474","article-title":"A case of profound neutropenia and agranulocytosis associated with off-label use of ceftaroline","volume":"71","author":"Yam","year":"2014","journal-title":"Am J Health Syst Pharm"},{"key":"2020081004074826300_CIT0004","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/phar.1435","article-title":"High incidence of discontinuations due to adverse events in patients treated with ceftaroline","volume":"34","author":"Jain","year":"2014","journal-title":"Pharmacotherapy"},{"key":"2020081004074826300_CIT0005","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/phar.1596","article-title":"Agranulocytosis with ceftaroline high-dose monotherapy or combination therapy with clindamycin","volume":"35","author":"Varada","year":"2015","journal-title":"Pharmacotherapy"},{"key":"2020081004074826300_CIT0006","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1093\/jac\/dkw062","article-title":"High incidence of neutropenia in patients with prolonged ceftaroline exposure","volume":"71","author":"Furtek","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2020081004074826300_CIT0007","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jaip.2016.03.008","article-title":"Adverse drug reactions associated with ceftaroline use: a 2-center retrospective cohort","volume":"4","author":"Blumenthal","year":"2016","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2020081004074826300_CIT0008","doi-asserted-by":"crossref","first-page":"e02015","DOI":"10.1128\/AAC.02015-16","article-title":"Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"61","author":"Zasowski","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081004074826300_CIT0009","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1128\/AAC.01471-15","article-title":"Neutropenia associated with long-term ceftaroline use","volume":"60","author":"LaVie","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081004074826300_CIT0010","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/jac\/dkx452","article-title":"Comparative analysis of neutropenia in patients receiving prolonged treatment with ceftaroline","volume":"73","author":"Turner","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2020081004074826300_CIT0011","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1060028017735629","article-title":"Rate and incidence of adverse reactions associated with ceftaroline exposure: importance of cutaneous manifestations","volume":"52","author":"Jansen","year":"2018","journal-title":"Ann Pharmacother"},{"key":"2020081004074826300_CIT0012","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"2020081004074826300_CIT0013","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1086\/655827","article-title":"Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection","volume":"51","author":"Corey","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2020081004074826300_CIT0014","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1086\/657313","article-title":"Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia","volume":"51","author":"File","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2020081004074826300_CIT0015","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1093\/jac\/dkw333","article-title":"A phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities","volume":"71","author":"Dryden","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2020081004074826300_CIT0016","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1093\/jac\/dkw326","article-title":"Outpatient use of ceftaroline fosamil versus vancomycin for osteoarticular infection: a matched cohort study","volume":"71","author":"Athans","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2020081004074826300_CIT0017","author":"Ceftriaxone [package insert]","year":"2013"},{"key":"2020081004074826300_CIT0018","first-page":"84","article-title":"Clinical adverse effects during ceftriaxone therapy","volume":"77","author":"Moskovitz","year":"1984","journal-title":"Am J Med"},{"key":"2020081004074826300_CIT0019","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/infdis\/160.3.433","article-title":"Once-daily therapy with ceftriaxone compared with daily multiple-dose therapy with cefotaxime for serious bacterial infections: a randomized, double-blind study","volume":"160","author":"Mandell","year":"1989","journal-title":"J Infect Dis"},{"key":"2020081004074826300_CIT0020","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1093\/jac\/dkv130","article-title":"Comparative outcomes of \u03b2-lactam antibiotics in outpatient parenteral antibiotic therapy: treatment success, readmissions and antibiotic switches","volume":"70","author":"Lee","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2020081004074826300_CIT0021","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/jac\/dky553","article-title":"Tolerability of high-dose ceftriaxone in CNS infections: a prospective multicenter cohort study","volume":"74","author":"Le Turnier","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2020081004074826300_CIT0022","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1093\/cid\/cit949","article-title":"Antibiotic hypersensitivity reactions and approaches to desensitization","volume":"58","author":"Legendre","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2020081004074826300_CIT0023","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4103\/2231-4040.70513","article-title":"The facts about penicillin allergy: a review","volume":"1","author":"Bhattacharya","year":"2010","journal-title":"J Adv Pharm Technol Res"},{"key":"2020081004074826300_CIT0024","author":"Teflaro (ceftaroline fosamil) [package insert]","year":"2018"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofz279\/28836504\/ofz279.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/7\/ofz279\/33589972\/ofz279.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/7\/ofz279\/33589972\/ofz279.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T21:41:36Z","timestamp":1721425296000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofz279\/5519766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,13]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofz279","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2019,6,13]]},"article-number":"ofz279"}}